Abstract:Kirsten rats sarcoma viral oncogene (KRAS), the first discovered human oncogene, has long been recognized as "undruggable". KRAS mutations frequently occur in multiple human cancers including non-small cell lung cancer(NSCLC), colorectal cancer(CRC) and pancreatic ductal adenocarcinoma(PDAC), functioning as a "molecule switch" determining the activation of various oncogenic signaling pathways. Except for its intrinsic pro-tumorigenic role, KRAS alteration also exhibits an unique immune signature characterized by elevated PD-L1 level and high tumor mutational burden(TMB). KRAS mutation shape an immune suppressive microenvironment by impeding effective T cells infiltration and recruiting suppressive immune cells including myeloid-derived suppressor cells(MDSCs), regulatory T cells(Tregs), cancer associated fibroblasts(CAFs). In immune checkpoint inhibitor(ICI) era, NSCLC patients with mutated KRAS tend to be more responsive to ICI than patients with intact KRAS. The hallmark for KRAS mutation is the existence of multiple kinds of co-mutations. Different types of co-alterations have distinct tumor microenvironment(TME) signatures and responses to ICI. TP53 co-mutation possess a "hot" TME and achieve higher response to immunotherapy while other loss of function mutation correlated with a "colder" TME and a poor outcome to ICI-based therapy. The groundbreaking discovery of KRAS G12C inhibitors significantly improved outcomes for this KRAS subtype even though efficacy was limited to NSCLC patients. KRAS G12C inhibitors also restore the suppressive TME, creating an opportunity for combinations with ICI. However, an inevitable challenge to KRAS inhibitors is drug resistance. Promising combination strategies such as combination with SHP2 is an approach deserve further exploration because of their immune modulatory effect.

The Function of RAS Mutation in Cancer and Advances in Its Drug Research

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

KRAS mutation: from undruggable to druggable in cancer

RAS‐targeted cancer therapy: Advances in drugging specific mutations

Emerging strategies to target RAS signaling in human cancer therapy

RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms

Targeting RAS Phosphorylation in Cancer Therapy: Mechanisms and Modulators

Development and safety of investigational and approved drugs targeting the RAS function regulation in RAS mutant cancers

Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways

Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

The current state of the art and future trends in RAS-targeted cancer therapies

From bench to bedside: current development and emerging trend of KRAS-targeted therapy

Targeting KRAS Mutant Cancers: from Druggable Therapy to Drug Resistance

Small molecular inhibitors for KRAS-mutant cancers

Targeting KRAS: Crossroads of Signaling and Immune Inhibition

Advances in KRAS mutation inhibition in metastatic colorectal cancer

Targeting KRAS in cancer

RAS-targeted therapies: is the undruggable drugged?

Unveiling the role of KRAS in tumor immune microenvironment

Targeting KRASG12D Mutation in Non-Small Cell Lung Cancer: Molecular Mechanisms and Therapeutic Potential